journal article·2016-09-13

Reply to “Evaluation of nanomedicines: stick to the basics”

Stefan Wilhelm, Anthony J. Tavares, Warren C. W. Chan

Nature Reviews Materials· Volume 1· Issue 10
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (7)

Show source-provided references
1. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).10.1038/natrevmats.2016.14 ↗
2. McNeil, S. Correspondence to the editor. Nat. Rev. Mater. http://dx.doi.org/10.1038/natrevmats.2016.73 (2016).10.1038/natrevmats.2016.73 ↗
3. Petersen, G. H., Alzghari, S. K., Chee, W., Sankari, S. S. & La-Beck, N. M. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J. Control. Release 232, 255–264 (2016).10.1016/j.jconrel.2016.04.028 ↗
4. [No authors listed.] A billion dollar punt. Nat. Biotechnol. 24, 1453 (2006).10.1038/nbt1206-1453 ↗
5. Carroll, J. Merck writes off RNAi, punts Sirna to Alnylam for $175M. FierceBiotech http://www.fiercebiotech.com/financials/merck-writes-off-rnai-punts-sirna-to-alnylam-for-175m (updated 4 Jul 2016).
6. Brunton, L. L., Chabner, B. & Knollmann, B. C. Goodman & Gilman's the Pharmacological Basis of Therapeutics (McGraw-Hill Medical, 2011).
7. Sykes, E. A. et al. Tailoring nanoparticle designs to target cancer based on tumor pathophysiology. Proc. Natl Acad. Sci. USA 113, E1142–E1151 (2016).10.1073/pnas.1521265113 ↗